IL92138A - Pharmaceutical preparations containing pyroxacam and their preparation - Google Patents

Pharmaceutical preparations containing pyroxacam and their preparation

Info

Publication number: IL92138A
Authority: IL; Israel
Prior art keywords: mass; parts; active ingredient; particle size; piroxicam
Prior art date: 1988-10-28

Application number

IL9213889A

Other languages

English (en)

Hebrew (he)

Other versions

IL92138A0 (en

Original Assignee

Egyt Gyogyszervegyeszeti Gyar

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-10-28

Filing date

1989-10-27

Publication date

1994-08-26

1989-10-27 Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar

1990-07-12 Publication of IL92138A0 publication Critical patent/IL92138A0/xx

1994-08-26 Publication of IL92138A publication Critical patent/IL92138A/en

Links

238000002360 preparation method Methods 0.000 title claims description 10
239000008194 pharmaceutical composition Substances 0.000 title claims description 8
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 title description 31
229960002702 piroxicam Drugs 0.000 title description 28
239000000203 mixture Substances 0.000 claims description 40
239000002775 capsule Substances 0.000 claims description 35
239000004480 active ingredient Substances 0.000 claims description 34
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 30
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 24
239000002245 particle Substances 0.000 claims description 17
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 16
229930195725 Mannitol Natural products 0.000 claims description 16
239000000594 mannitol Substances 0.000 claims description 16
235000010355 mannitol Nutrition 0.000 claims description 16
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 14
239000008101 lactose Substances 0.000 claims description 14
235000019359 magnesium stearate Nutrition 0.000 claims description 12
229920002261 Corn starch Polymers 0.000 claims description 11
239000008120 corn starch Substances 0.000 claims description 11
239000000377 silicon dioxide Substances 0.000 claims description 11
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 10
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 10
238000000034 method Methods 0.000 claims description 6
238000011049 filling Methods 0.000 claims description 5
238000003825 pressing Methods 0.000 claims description 5
239000007884 disintegrant Substances 0.000 claims description 4
239000000314 lubricant Substances 0.000 claims description 4
239000004094 surface-active agent Substances 0.000 claims description 4
238000004090 dissolution Methods 0.000 description 12
239000000843 powder Substances 0.000 description 6
229910002016 Aerosil® 200 Inorganic materials 0.000 description 4
238000000265 homogenisation Methods 0.000 description 4
FVTSYHPRVGNAQI-UHFFFAOYSA-N 2-aminoethanol;4-hydroxy-2-methyl-1,1-dioxo-n-pyridin-2-yl-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound NCCO.OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 FVTSYHPRVGNAQI-UHFFFAOYSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000013078 crystal Substances 0.000 description 3
238000009826 distribution Methods 0.000 description 3
239000011148 porous material Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
229920000881 Modified starch Polymers 0.000 description 2
238000005299 abrasion Methods 0.000 description 2
230000000694 effects Effects 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
UDKXQFAVKLBFDG-UHFFFAOYSA-L magnesium;sodium;dodecyl sulfate;octadecanoate Chemical compound [Na+].[Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCCCCCCC([O-])=O UDKXQFAVKLBFDG-UHFFFAOYSA-L 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
238000005550 wet granulation Methods 0.000 description 2
229910000906 Bronze Inorganic materials 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000003356 anti-rheumatic effect Effects 0.000 description 1
239000003435 antirheumatic agent Substances 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000010974 bronze Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
KUNSUQLRTQLHQQ-UHFFFAOYSA-N copper tin Chemical compound [Cu].[Sn] KUNSUQLRTQLHQQ-UHFFFAOYSA-N 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
150000002084 enol ethers Chemical class 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
238000009472 formulation Methods 0.000 description 1
210000004051 gastric juice Anatomy 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
239000002788 histamine agent Substances 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
-1 piroxicam ethylenediamine salt Chemical class 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
238000005029 sieve analysis Methods 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000001665 trituration Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pain & Pain Management (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Rheumatology (AREA)
Inorganic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

IL9213889A 1988-10-28 1989-10-27 Pharmaceutical preparations containing pyroxacam and their preparation IL92138A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
HU885621A HU200926B (en)	1988-10-28	1988-10-28	Pharmaceutical composition comprising piroxicam and lactose for use in making tablets or capsules

Publications (2)

Publication Number	Publication Date
IL92138A0 IL92138A0 (en)	1990-07-12
IL92138A true IL92138A (en)	1994-08-26

Family

ID=10970484

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9213889A IL92138A (en)	1988-10-28	1989-10-27	Pharmaceutical preparations containing pyroxacam and their preparation

Country Status (9)

Country	Link
JP (1)	JPH02172918A (de)
AT (1)	AT399277B (de)
CA (1)	CA2001673C (de)
DE (1)	DE3936112C2 (de)
FR (1)	FR2638357B1 (de)
GB (1)	GB2224207B (de)
HU (1)	HU200926B (de)
IL (1)	IL92138A (de)
IT (1)	IT1239542B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2642486B2 (ja) *	1989-08-04	1997-08-20	田辺製薬株式会社	難溶性薬物の超微粒子化法
JP2964195B2 (ja) *	1992-04-28	1999-10-18	エスエス製薬株式会社	ピロキシカム錠及びその製造法
DE19603402A1 (de) *	1995-02-24	1996-08-29	Basf Ag	Weichgelatinekapseln
DE69733476T2 (de)	1996-06-14	2006-03-23	Kyowa Hakko Kogyo Co., Ltd.	Im munde schnellzerfallende tablette
US8071128B2 (en)	1996-06-14	2011-12-06	Kyowa Hakko Kirin Co., Ltd.	Intrabuccally rapidly disintegrating tablet and a production method of the tablets
WO1999052491A1 (en) *	1998-04-08	1999-10-21	Kyowa Hakko Kogyo Co., Ltd.	Tablet manufacturing method and tablet
JP2000095674A (ja) *	1998-09-22	2000-04-04	Sato Pharmaceutical Co Ltd	口腔内崩壊時間短縮化錠剤の製造方法及び装置
US9358214B2 (en)	2001-10-04	2016-06-07	Adare Pharmaceuticals, Inc.	Timed, sustained release systems for propranolol
MXPA05006513A (es) *	2002-12-16	2005-09-08	Kissei Pharmaceutical	Farmaco solido para uso oral.
US8367111B2 (en)	2002-12-31	2013-02-05	Aptalis Pharmatech, Inc.	Extended release dosage forms of propranolol hydrochloride
US8747895B2 (en)	2004-09-13	2014-06-10	Aptalis Pharmatech, Inc.	Orally disintegrating tablets of atomoxetine
US9884014B2 (en)	2004-10-12	2018-02-06	Adare Pharmaceuticals, Inc.	Taste-masked pharmaceutical compositions
NZ589750A (en)	2004-10-21	2012-07-27	Aptalis Pharmatech Inc	Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en)	2005-05-02	2015-10-20	Adare Pharmaceuticals, Inc.	Timed, pulsatile release systems
EP1920786B8 (de)	2005-07-25	2012-02-22	Otsuka Pharmaceutical Co., Ltd.	Orales präparat zur messung der fähigkeit pyrimidin zu metabolisieren
SG10201407965XA (en)	2009-12-02	2015-02-27	Aptalis Pharma Ltd	Fexofenadine microcapsules and compositions containing them
JP6352188B2 (ja)	2012-08-20	2018-07-04	大塚製薬株式会社	糖代謝能の測定方法及びそれに使用する組成物
EP2975400B1 (de)	2013-03-15	2019-09-04	Otsuka Pharmaceutical Co., Ltd.	Zusammensetzung zur verwendung in einem verfahren zur messung des zucker- / fettsäureverbrennungsverhältnisses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3591584A (en) *	1968-08-27	1971-07-06	Pfizer	Benzothiazine dioxides
GB1308533A (en) *	1969-06-02	1973-02-21	Pfizer	Benzothiazine dioxides as anti-thombotic agents
JPS55129221A (en) *	1979-03-29	1980-10-06	Kaken Pharmaceut Co Ltd	Preparation of oral preparation containing hardly soluble medicine
US4350689A (en) *	1980-02-15	1982-09-21	American Cyanamid Company	Combinations of agents which give enhanced anti-inflammatory activity
US4434164A (en) *	1981-06-01	1984-02-28	Pfizer Inc.	Crystalline benzothiazine dioxide salts
RO88420A (ro) *	1983-04-25	1986-01-30	Pfizer Inc,Us	Procedeu pentru prepararea unor saruri bazice de piroxican depuse pe suporturi farmaceutice
DE3419128A1 (de) *	1984-05-23	1985-11-28	Bayer Ag, 5090 Leverkusen	Dihydropyridinpraeparate und verfahren zu ihrer herstellung
CH663899A5 (fr) *	1985-03-20	1988-01-29	Nestle Sa	Procede pour la preparation d'une composition a base d'un principe actif de faible hydrosolubilite finement divise.
ES545221A0 (es) *	1985-07-02	1986-01-01	Ferrer Int	Procedimiento de obtencion de particulas de 4-hidroxi-2-me- til-n-2-piridil-2h-1,2-benzotiazina-3-carboxamida-1,1-dioxi-do(piroxicam) recubiertas

1988
- 1988-10-28 HU HU885621A patent/HU200926B/hu unknown
1989
- 1989-10-19 JP JP1270514A patent/JPH02172918A/ja active Pending
- 1989-10-27 CA CA002001673A patent/CA2001673C/en not_active Expired - Fee Related
- 1989-10-27 IL IL9213889A patent/IL92138A/en not_active IP Right Cessation
- 1989-10-27 IT IT22164A patent/IT1239542B/it active IP Right Grant
- 1989-10-27 GB GB8924286A patent/GB2224207B/en not_active Expired - Lifetime
- 1989-10-27 AT AT0247489A patent/AT399277B/de not_active IP Right Cessation
- 1989-10-27 FR FR8914117A patent/FR2638357B1/fr not_active Expired - Fee Related
- 1989-10-30 DE DE3936112A patent/DE3936112C2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
GB2224207B (en)	1992-06-10
GB2224207A (en)	1990-05-02
FR2638357B1 (fr)	1993-10-22
HUT51143A (en)	1990-04-28
AT399277B (de)	1995-04-25
IT8922164A0 (it)	1989-10-27
CA2001673A1 (en)	1990-04-28
IT1239542B (it)	1993-11-05
IL92138A0 (en)	1990-07-12
IT8922164A1 (it)	1991-04-27
HU200926B (en)	1990-09-28
DE3936112A1 (de)	1990-05-31
FR2638357A1 (fr)	1990-05-04
GB8924286D0 (en)	1989-12-13
DE3936112C2 (de)	1999-02-18
ATA247489A (de)	1994-09-15
JPH02172918A (ja)	1990-07-04
CA2001673C (en)	1996-08-27

Legal Events

Date	Code	Title	Description
2000-12-06	RH	Patent void

Publication	Publication Date	Title
CA2001673C (en)	1996-08-27	Pharmaceutical composition containing piroxicam
RU2181590C2 (ru)	2002-04-27	Фармацевтические композиции, содержащие ирбесартан
KR940002659B1 (ko)	1994-03-28	치료제 조성물의 제조방법
AU684522B2 (en)	1997-12-18	Pharmaceutical thermal infusion process
US9017722B2 (en)	2015-04-28	Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone
CA1306686C (en)	1992-08-25	Pharmaceutical composition containing ibuprofen
US5824344A (en)	1998-10-20	Pharmaceutical thermal infusion granules
PL200957B1 (pl)	2009-02-27	Kompozycja farmaceutyczna celecoxib'u i zastosowanie kompozycji farmaceutycznej
US6656929B1 (en)	2003-12-02	Pharmaceutical composition with a synthetic natural progesterone and oestradiol base and its preparation process
TWI415633B (zh)	2013-11-21	Solid preparations containing enteric solid dispersions
IL96995A (en)	1994-11-11	Pharmaceutical compositions containing pimobendan and their preparation
CZ300558B6 (cs)	2009-06-17	Tabletová kompozice nesteroidního protizánetlivého léciva a zpusob její prípravy
JPH02164824A (ja)	1990-06-25	分散性製剤
MXPA04011634A (es)	2005-07-05	Regimenes de tratamiento con bazedoxifeno.
US6365196B1 (en)	2002-04-02	Controlled release solid dosage forms of lithium carbonate
US5827537A (en)	1998-10-27	Pharmaceutical thermal infusion process
JP2002068983A (ja)	2002-03-08	８−クロロ−６，１１−ジヒドロ−１１−（４−ピペリジリデン）−５Ｈ−ベンゾ［５，６］シクロヘプタ［１，２−ｂ］ピリジンの経口用組成物
CZ287149B6 (en)	2000-09-13	Pharmaceutical preparation containing gemfibrozil
NO318575B1 (no)	2005-04-11	Stabile sammensetninger som omfatter levosimendan og alginsyre
JP4429262B2 (ja)	2010-03-10	フェノフィブラートの固体分散体
US6056974A (en)	2000-05-02	Rapid-release S1452 tablets
DK165168B (da)	1992-10-19	Fremgangsmaade til fremstilling af et basesalt af piroxicam aflejret paa en farmaceutisk acceptabel baerer
JPH10226644A (ja)	1998-08-25	医薬組成物
CZ289856B6 (cs)	2002-04-17	Farmaceutický prostředek na bázi inhibitoru 5alfa-reduktázy
KR20180112139A (ko)	2018-10-12	바제독시펜 또는 그의 약제학적으로 허용가능한 염, 및 콜레칼시페롤 또는 그의 약제학적으로 허용가능한 염을 포함하는 복합제제